Biotech companies with no product are worth more

Biotech companies yet to release a product are worth far more than those that have, analysts have said.

Davis Smythe III at California based Investeromics, who specialises in biotech investments, had this to say:

“It makes sense when you think about it.  When a biotech company has no product, there is a 100% possibility that they may produce something amazing.  However, when they reveal their first product, and it is invariably a bit crappy, there’s a 100% certainty that they’re worth very little”.

Smythe pointed to the prenatal testing sector who “just do sequencing; anyone can do that these days”, and the numerous genome interpretation companies who “just run a few free software tools” as examples.

“When these companies first came out, it was really exciting; we were desperate to give them cash.  Who knew that they basically had no new ideas?  We’re investors, not scientists.  We don’t want to know the truth.  Give me a biotech with no product any day!”

The biotech sector has a long history of over-promising and delivering little.  Many expect to see more unrealistic announcements at the 15th annual Advances in Genome Biology and Technology (AGBT) meeting next week.  Traditionally, biotech companies use AGBT to announce things they can’t do yet, and probably never will.

This entry was posted in Not news. Bookmark the permalink.

One Response to Biotech companies with no product are worth more

  1. Clutman says:

    Truth is stranger than fiction…indeed!

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s